Latent class analysis identifies functional decline with Amsterdam IADL in preclinical Alzheimer's disease

Abstract Introduction Trials in Alzheimer's disease (AD) now include participants at the earliest stages to prevent further decline. However, the lack of tools sensitive to subtle functional changes in early‐stage AD hinders the development of new therapies as it is difficult to prove their cli...

Full description

Saved in:
Bibliographic Details
Main Authors: Sarah‐Christine Villeneuve, Marion Houot, Federica Cacciamani, Merike Verrijp, Bruno Dubois, Sietske Sikkes, Stéphane Epelbaum, MEMENTO study group and the INSIGHT‐preAD study group, Hovagim Bakardjian, Habib Benali, Hugo Bertin, Joel Bonheur LaurieBoukadida, Nadia Boukerrou, Enrica Cavedo, Patrizia Chiesa, Olivier Colliot, Marion Dubois, Geoffroy Gagliardi, Remy Genthon, Marie‐Odile Habert, Harald Hampel, Aurélie Kas, Foudil Lamari, Marcel Levy, Simone Lista, Christiane Metzinger, Fanny Mochel, Francis Nyasse, Catherine Poisson, Marie‐Claude Potier, Marie Revillon, Antonio Santos, Katia Santos Andrade, Marine Sole, Mohmed Surtee, Michel Thiebaud de Schotten, Andrea Vergallo, Nadjia Younsi
Format: Article
Language:English
Published: Wiley 2019-01-01
Series:Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Subjects:
Online Access:https://doi.org/10.1016/j.trci.2019.08.009
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Introduction Trials in Alzheimer's disease (AD) now include participants at the earliest stages to prevent further decline. However, the lack of tools sensitive to subtle functional changes in early‐stage AD hinders the development of new therapies as it is difficult to prove their clinical relevance. Methods We assessed functional changes over three years in 289 elderly memory complainers from the Investigation of Alzheimer's Predictors in subjective memory complainers cohort using the Amsterdam Instrumental‐Activities‐of‐Daily‐Living questionnaire (A‐IADL‐Q). Results No overall functional decline related to AD imaging markers was evidenced. However, five distinct classes of A‐IADL‐Q trajectories were identified. The largest class (212 [73.4%]) had stable A‐IADL‐Q scores over 3 years. A second group (23 [8.0%]) showed a persistent functional decline, higher amyloid load (P = .0005), and lower education (P = .0392). Discussion The A‐IADL‐Q identified a subtle functional decline in asymptomatic at‐risk AD individuals. This could have important implications in the field of early intervention in AD.
ISSN:2352-8737